Antineoplastic - B-cell lymphoma-2 (BCL-2) inhibitors

Antineoplastic B-cell lymphoma-2 (BCL-2) inhibitors are a class of targeted antineoplastic agents designed to promote apoptosis in malignant cells

Antineoplastic B-cell lymphoma-2 (BCL-2) inhibitors are a class of targeted antineoplastic agents designed to promote apoptosis in malignant cells By selectively binding to and blocking the anti-apoptotic BCL-2 protein, these agents liberate pro-apoptotic effectors to permeabilize the mitochondrial outer membrane and trigger programmed cell death

Antineoplastic B-cell lymphoma-2 (BCL-2) inhibitors are a class of targeted antineoplastic agents designed to promote apoptosis in malignant cells By selectively binding to and blocking the anti-apoptotic BCL-2 protein, these agents liberate pro-apoptotic effectors to permeabilize the mitochondrial outer membrane and trigger programmed cell death Clinically, they serve as a core therapeutic strategy in hematologic malignancies characterized by pathological BCL-2 overexpression, most notably chro...

By selectively binding to and blocking the anti-apoptotic BCL-2 protein, these agents liberate pro-apoptotic effectors to permeabilize the mitochondrial outer membrane and trigger programmed cell death Clinically, they serve as a core therapeutic strategy in hematologic malignancies characterized by pathological BCL-2 overexpression, most notably chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia

Clinically, they serve as a core therapeutic strategy in hematologic malignancies characterized by pathological BCL-2 overexpression, most notably chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia